Register for our free email digests:
Latest From Sunovion Pharmaceuticals Inc.
Analyst speculates that Gilead could move to acquire Spring Bank if combo trial yields promising data for functional cure of hepatitis B. Eisai in-licenses PARP inhibitor with potential in breast cancer from Oncology Venture, while Sunovion out-licenses three corticosteroid products to Covis.
Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.
GSK's deal with Exscientia will see the Scottish artificial intelligence pioneer discover new small molecules against targets selected by the big pharma. Exscientia is already working with Sanofi, Evotec, Sumitomo Dainippon Pharma and Sunovion across a range of disease areas, and is in talks with others.
Keeping Track: Clarus, Agile and Sunovion Look To Bounce Back From CRLs; FDA To Review Rituximab Biosimilar
The latest drug development news and highlights from our US FDA Performance Tracker.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Kaiser Permanente
- Senior Management
David M Lawrence, CEO
Robert E Briggs, SVP, CFO
Susan E Porth, SVP, Fin.
William Caswell, VP, Mktg. & Bus. Dev.
- Contact Info
Phone: (415) 271-5910
1 Kaiser Plaza
Oakland, CA 94612-2703
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.